Cargando…

Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy

Nowadays immunotherapy is considered the tip of the arrow as treatment for non-small cell lung cancer for inoperable patients. Programmed death-ligand 1 is considered a valuable marker for the success of immunotherapy. The higher the score ≥50% the more successful the treatment will be. However; pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zarogoulidis, Paul, Kosmidis, Christoforos, Perdikouri, Eleni-Isidora, Hohemforst-Schmidt, Wolfgang, Sardeli, Chrisanthi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489498/
https://www.ncbi.nlm.nih.gov/pubmed/36161237
http://dx.doi.org/10.1016/j.rmcr.2022.101741
_version_ 1784792896160923648
author Zarogoulidis, Paul
Kosmidis, Christoforos
Perdikouri, Eleni-Isidora
Hohemforst-Schmidt, Wolfgang
Sardeli, Chrisanthi
author_facet Zarogoulidis, Paul
Kosmidis, Christoforos
Perdikouri, Eleni-Isidora
Hohemforst-Schmidt, Wolfgang
Sardeli, Chrisanthi
author_sort Zarogoulidis, Paul
collection PubMed
description Nowadays immunotherapy is considered the tip of the arrow as treatment for non-small cell lung cancer for inoperable patients. Programmed death-ligand 1 is considered a valuable marker for the success of immunotherapy. The higher the score ≥50% the more successful the treatment will be. However; previous studies have presented favorable data even for those patients where the programmed death-ligand 1 was ≤50% or even 0%, therefore it can be administered as first line treatment in these patients with the addition of chemotherapy or radiotherapy. Other treatment modalities are tested as surrogates like gene therapy with immunotherapy to improve the results in patients with programmed death-ligand 1 was ≤50% or even 0%. The main issue for these patients is an adverse effect pneumonitis, in case we will present the valuable method of lung parenchyma sampling with cryobiopsy for early diagnosis of immunotherapy induced pneumonitis.
format Online
Article
Text
id pubmed-9489498
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94894982022-09-22 Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy Zarogoulidis, Paul Kosmidis, Christoforos Perdikouri, Eleni-Isidora Hohemforst-Schmidt, Wolfgang Sardeli, Chrisanthi Respir Med Case Rep Case Report Nowadays immunotherapy is considered the tip of the arrow as treatment for non-small cell lung cancer for inoperable patients. Programmed death-ligand 1 is considered a valuable marker for the success of immunotherapy. The higher the score ≥50% the more successful the treatment will be. However; previous studies have presented favorable data even for those patients where the programmed death-ligand 1 was ≤50% or even 0%, therefore it can be administered as first line treatment in these patients with the addition of chemotherapy or radiotherapy. Other treatment modalities are tested as surrogates like gene therapy with immunotherapy to improve the results in patients with programmed death-ligand 1 was ≤50% or even 0%. The main issue for these patients is an adverse effect pneumonitis, in case we will present the valuable method of lung parenchyma sampling with cryobiopsy for early diagnosis of immunotherapy induced pneumonitis. Elsevier 2022-09-15 /pmc/articles/PMC9489498/ /pubmed/36161237 http://dx.doi.org/10.1016/j.rmcr.2022.101741 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Zarogoulidis, Paul
Kosmidis, Christoforos
Perdikouri, Eleni-Isidora
Hohemforst-Schmidt, Wolfgang
Sardeli, Chrisanthi
Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy
title Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy
title_full Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy
title_fullStr Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy
title_full_unstemmed Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy
title_short Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy
title_sort cryobiopsy for pneumonitis diagnosis in nsclc immunotherapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489498/
https://www.ncbi.nlm.nih.gov/pubmed/36161237
http://dx.doi.org/10.1016/j.rmcr.2022.101741
work_keys_str_mv AT zarogoulidispaul cryobiopsyforpneumonitisdiagnosisinnsclcimmunotherapy
AT kosmidischristoforos cryobiopsyforpneumonitisdiagnosisinnsclcimmunotherapy
AT perdikourieleniisidora cryobiopsyforpneumonitisdiagnosisinnsclcimmunotherapy
AT hohemforstschmidtwolfgang cryobiopsyforpneumonitisdiagnosisinnsclcimmunotherapy
AT sardelichrisanthi cryobiopsyforpneumonitisdiagnosisinnsclcimmunotherapy